Retinol and Retinyl Esters: Cosmetics Regulation EU Concentration Limits

Spectra Cosmetic Compliance

This restriction was introduced by an amendment to the EU Cosmetics Regulation. Confirm current detail for your specific products as positions can evolve.

What retinol is

Retinol is a derivative of vitamin A part of the retinoid family valued in skincare for supporting cell turnover and collagen and for its anti ageing and skin renewing effects. The regulation's change also covers two related retinyl esters retinyl acetate and retinyl palmitate which are other forms of vitamin A used in cosmetics. Collectively these are the vitamin A ingredients addressed. This change is part of the eu cosmetic regulation framework that governs which ingredients can be used and at what levels in cosmetic products sold across the European Union.

Retinol and its esters are widely used in serums creams and lotions, often marketed for their performance on fine lines and skin texture. Their popularity means the new limits affect a large number of products across the skincare market making this a significant change for the sector.

The new concentration limits

The EU now sets maximum limits on how much retinol retinyl acetate and retinyl palmitate a product can contain measured together as retinol equivalent (RE):

• Body lotion: maximum 0.05% RE
• Other leave-on and rinse-off products (including facial products): maximum 0.3% RE

Why retinol equivalent ?

Retinol retinyl acetate and retinyl palmitate are all different forms of vitamin A. Retinol equivalent adds up their combined strength into one number so no matter which form, or combination a product uses the total vitamin A activity must stay under the applicable limit. These limits exist under the wider cosmetics regulation to keep exposure within levels considered safe.

What this means for brands

If your product used higher concentrations before you'll likely need to reformulate.

You need to calculate your product's total retinol equivalent concentration.

You then need to check it against the correct limit for your product type.

Why the limits were introduced

The restriction responds to a scientific concern about cumulative vitamin A exposure. Vitamin A is obtained from diet and supplements as well as cosmetics and there is an upper level of intake above which it may pose risks. The Scientific Committee on Consumer Safety concluded that vitamin A is safe in cosmetics up to the specified levels, but that overall population exposure could exceed the recommended upper intake. This is a good example of how the scientific committee on consumer safety informs regulatory change: its opinion directly shaped the new limits all in service of the underlying goal to protect consumers.

So the limits are about total exposure not a specific hazard of cosmetic use at the permitted levels. The cosmetic contribution is being controlled to help keep total vitamin A intake within safe bounds. This is why the response was to cap concentrations and warn consumers rather than to ban the ingredient. It is a clear illustration of how a safety assessment can lead to an ingredient being banned or restricted rather than removed outright, once the underlying science is weighed.

The mandatory warning label

Alongside the concentration limits products containing these vitamin A ingredients must carry a mandatory warning: wording to the effect of Contains vitamin A. Consider your daily intake before use. This alerts consumers to the cumulative exposure issue prompting them to consider their total vitamin A intake from all sources. This mandatory wording is one of the labelling requirements that now applies to any affected product.

This warning is a labelling requirement that must appear on affected products. It links directly to the reason for the restriction cumulative exposure by giving consumers the information to manage their own intake. Brands must add this warning to affected products' labels and reflect it in the product's cosmetic product safety report and product information file as part of the underlying documentation.

The deadlines

The change is phased. From 1 November 2025 new cosmetic products placed on the EU market must comply with the concentration limits and carry the warning. Products already on the market have a longer transition, with non compliant products needing to be off the market by 1 May 2027. So there is a placing on market deadline in late 2025 and a sell through period into 2027. The concentration limits and warning requirement came into force for new products from that November 2025 date.

This means the placing on market deadline has already arrived new EU products must now comply with the final sell through deadline still ahead. Brands should ensure new and reformulated products meet the limits and carry the warning and that non compliant stock clears before the 2027 deadline. Confirm the exact dates for your products since competent authorities in individual member states are responsible for enforcing these deadlines through market surveillance.

The UK position

This is an EU measure. Northern Ireland following EU rules is covered by it. At the time of writing the position in Great Britain may differ, as the UK sets its own rules and may or may not have introduced an equivalent restriction. Brands selling retinol products in Great Britain should confirm the current GB requirement separately.

This is another example of potential post Brexit divergence: a significant EU ingredient restriction that does not automatically apply in Great Britain. Brands selling across both markets should track each market's position on retinol rather than assuming the EU rule applies UK wide. Confirming the GB position for retinol is advisable.

What brands need to do

The steps for EU market products are:

• Identify products containing retinol, retinyl acetate or retinyl palmitate.
• Calculate the retinol-equivalent concentration and check it against the applicable limit.
• Reformulate where necessary to bring products within the limits.
• Add the mandatory warning to affected products.
• Update the CPSR, PIF and label accordingly.
• Ensure the applicable transitional deadlines are met.

Because the placing on market deadline has passed for the EU this is an active obligation for products being placed on the EU market now, not a future one. Brands with retinol ranges should ensure they are already compliant for new EU products and are clearing any non compliant stock before the final deadline. This is exactly the kind of change that triggers reassessment of existing products and it's a reminder that the Responsible Person should keep the safety report and supporting file up to date whenever an ingredient restriction changes. Regulation (EC) No 1223/2009 remains the overarching framework within which these amendments sit.

Retinol in context: actives under review

The retinol restriction is part of a broader trend of popular actives coming under regulatory review. As the science on ingredient exposure and safety develops and as regulators assess widely used substances more actives are being restricted or having conditions placed on their use. Retinol is a prominent example but it is not the only active ingredient to face new limits in recent regulatory activity across the european market.

For brands built around active ingredients this means active led products carry an inherent regulatory sensitivity: a popular effective active can become subject to new limits requiring reformulation. Building a product entirely around a single active at a high concentration carries more regulatory risk than a more balanced formulation. A qualified safety assessor reviewing the formulation is often the first to flag this kind of exposure risk.

The practical response is to keep active led products under review as the regulatory picture develops, and to monitor the pipeline of scientific opinions that tends to precede restrictions. Brands that anticipate these changes watching which actives are under assessment can plan reformulations in an orderly way rather than reacting to a deadline.

References: Commission Regulation (EU) 2024/996 placed on the market tamending Regulation (EC) No 1223/2009 Annex III (EUR-Lex) SCCS opinion on vitamin A. Verified July 2026 confirm current detail including the GB position before acting. General information only not legal advice.